Lee Han-Soo writing for Korea Biomedical Review notes that Genexine and NeoImmune Tech have received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials of combination treatment of HyLeukin-7, an immunotherapeutic drug candidate and standard therapies, for newly diagnosed high-grade glioma patients. HyLeukin-7 is a new drug pipeline that combined optimized interleukin-7(IL-7) with Hybrid Fc (hyFc), an original technology owned by Genexine. The drug recently received approval by the FDA for brain cancer patients. The clinical trial led by Johns Hopkins Hospital administers a single dose of Hyleukin-7 alone and aims to evaluate the safety and mechanism of action.
Based in South Korea, Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics. Formed in 1999, they have raised approximately $70 million and estimated revenues are $10 million.